Phosphatidylinositol 3-kinase inhibitors
Granted: June 4, 2019
Patent Number:
10308639
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m?, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or…
Methods of treating hepatitis E viral infection
Granted: June 4, 2019
Patent Number:
10307438
Disclosed herein are methods of treating a hepatitis E viral infection comprising administering to a human subject in need thereof a therapeutically effective amount of the compound sofosbuvir, also known as (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. Some methods further comprise concomitantly administering ribavirin to the subject. In some methods, the…
Apoptosis signal-regulating kinase inhibitors
Granted: June 4, 2019
Patent Number:
10307427
The present invention relates to compounds of Formula (I): Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary…
HIV inhibitor compounds
Granted: May 21, 2019
Patent Number:
10294234
The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
Crystalline forms of tenofovir alafenamide
Granted: May 14, 2019
Patent Number:
10287307
The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
Toll like receptor modulator compounds
Granted: May 14, 2019
Patent Number:
10285990
The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
Tank-binding kinase inhibitor compounds
Granted: April 16, 2019
Patent Number:
10259811
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
2-(N-pyrazolo)adenosines with application as adenosine Areceptor agonists
Granted: April 16, 2019
Patent Number:
RE47351
N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.
Methods for treating arenaviridae and coronaviridae virus infections
Granted: April 9, 2019
Patent Number:
10251904
Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
Tank-binding kinase inhibitor compounds
Granted: April 9, 2019
Patent Number:
10253019
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
Methods for treating Filoviridae virus infections
Granted: April 9, 2019
Patent Number:
10251898
Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
Macrocyclic inhibitors of flaviviridae viruses
Granted: April 2, 2019
Patent Number:
10246486
Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
Macrocyclic inhibitors of flaviviridae viruses
Granted: April 2, 2019
Patent Number:
RE47334
Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
Human immunodeficiency virus neutralizing antibodies
Granted: March 26, 2019
Patent Number:
10239935
The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
Methods of treating liver disease
Granted: March 26, 2019
Patent Number:
10238636
The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ASK1 inhibitor in combination with a FXR agonist, to a patient in need thereof.
Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Granted: March 19, 2019
Patent Number:
RE47301
Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
Phosphatidylinositol 3-kinase inhibitors
Granted: March 12, 2019
Patent Number:
10227350
The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R1, R2, R3, R4, R5, and R6 are as described herein.
FXR (NR1H4) binding and activity modulating compounds
Granted: March 5, 2019
Patent Number:
10220027
The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
Phosphatidylinositol 3-kinase inhibitors
Granted: March 5, 2019
Patent Number:
10221197
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or…
Inhibitors of histone demethylases
Granted: March 5, 2019
Patent Number:
10221139
The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form
